Endocrinology Drugs Market
Endocrinology Drugs Market Forecasts to 2030 - Global Analysis By Therapy Area (Diabetes Drugs, Growth Hormone Disorders, Thyroid Hormone Disorder Drugs, Testosterone Replacement Therapy, Osteoporosis, Adrenal insufficiency, Hypogonadism and Other Therapy Areas), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies and Other Distribution Channels), Route of Administration, End User and By Geography.
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $6.25 BN |
|
Projected Year Value (2030) |
US $15.93 BN |
|
CAGR (2023 - 2030) |
14.3% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Endocrinology Drugs Market is accounted for $6.25 billion in 2023 and is expected to reach $15.93 billion by 2030 growing at a CAGR of 14.3% during the forecast period. Endocrinology drugs are pharmaceutical substances designed to target and regulate the functions of the endocrine system. These drugs are used to treat a wide range of endocrine disorders and conditions, such as diabetes, thyroid disorders, adrenal gland disorders, and hormonal imbalances. These drugs can be administered in various forms, including oral medications, injections, and topical treatments, depending on the specific condition and the hormone involved.
According to the International Diabetic Foundation (IDF) 2021 update, approximately 537 million adults (20-79 years) were living with diabetes in 2021.
Market Dynamics:
Driver:
Growing prevalence of endocrine disorders
The growing prevalence of endocrine disorders is a significant driver of the endocrinology drug market. Lifestyle changes, including sedentary behaviour and poor dietary habits, have led to an increase in conditions like diabetes and obesity, both of which often require endocrinology medications for management. The increasing prevalence of hormonal imbalances and associated diseases has raised concerns and been attributed to environmental factors, such as exposure to endocrine-disrupting substances. Furthermore, these combined factors create a sustained demand for endocrinology drugs, providing growth for pharmaceutical companies to develop and market innovative treatments that address the needs of an expanding patient population.
Restraint:
Research and development costs
Research and Development (R&D) costs are a significant restraint in the endocrinology drugs market. Developing new endocrinology medications demands substantial financial investments, often spanning many years and clinical trials. High R&D expenditures can lead to financial strain for pharmaceutical companies, especially if promising drugs fail in late-stage trials. These costs contribute to elevated drug prices, attracting scrutiny from healthcare payers and governments. The need for rigorous safety and efficacy testing further increases the financial burden. Balancing the imperative for innovation with the substantial R&D expenses is a challenging restraint, making it essential for pharmaceutical firms to carefully select and prioritize potential drug candidates in the highly competitive endocrinology market.
Opportunity:
Development of combination therapies
Combination therapies have emerged as a promising opportunity in the field of endocrinology, offering potential benefits for the treatment of various endocrine disorders. By combining different drugs or treatment approaches, combination therapies can provide synergistic effects, improving treatment outcomes and patient response rates. They can also help address issues such as drug resistance and reduce the risk of adverse effects associated with high doses of a single medication. Moreover, combination therapies offer the potential to target specific disease mechanisms or pathways simultaneously, leading to more comprehensive and personalised treatment strategies. This approach is especially relevant in the management of conditions like diabetes, thyroid disorders, and hormonal imbalances. With ongoing advancements in understanding endocrine disorders and the development of novel therapeutic agents, the exploration and development of combination therapies present a significant opportunity to optimise treatment outcomes in endocrinology. Thus, there is lucrative growth for market expansion.
Threat:
Regulatory challenges
Regulatory challenges present a substantial threat to the endocrinology market. The development, approval, and commercialization of endocrinology drugs are subject to stringent and evolving regulations. Regulatory agencies, such as the FDA, impose rigorous standards to ensure safety and efficacy, which can lead to protracted approval timelines and high compliance costs. Compliance with these standards demands substantial financial and human resources, potentially discouraging investment in research and development. Additionally, changes in regulatory requirements can impact the market landscape, necessitating constant adaptation. Thus, these challenges are hampering market growth.
Covid-19 Impact
The COVID-19 pandemic had a significant impact on the endocrinology drugs market. The healthcare system's focus on managing the virus led to disruptions in the diagnosis and treatment of endocrine disorders. Additionally, supply chain disruptions and drug shortages posed challenges in maintaining a steady supply of endocrinology drugs. However, the pandemic also accelerated telehealth adoption, offering new avenues for remote monitoring and prescription management. Ultimately, the endocrinology drugs market faced a complex landscape of delays, drug shortages, and evolving healthcare delivery models during the pandemic.
The Diabetes Drugs segment is expected to be the largest during the forecast period
The Diabetes Drugs segment is estimated to hold the largest share, owing to the increase in cases of diabetes, the rise in the development of diabetic drugs, and the increase in investment in the development of diabetic drug research. Also, the high prevalence of diabetes across the globe and the unavailability of promising and effective drug products for the treatment of diabetes spurs the growth of this segment. Furthermore, a rise in investments in the development of diabetic drugs by key players or government agencies is expected to fuel the growth of the segment. Hence, due to the rise in cases of diabetes and the increase in research funding for the development of diabetic drugs, the diabetes segment is expected to witness significant growth.
The Hospital Pharmacies segment is expected to have the highest CAGR during the forecast period
The Hospital Pharmacies segment is anticipated to have lucrative growth during the forecast period. Endocrinology drugs are designed to address hormonal imbalances and related conditions. In this segment, hospital pharmacies serve as key distribution points; ensuring patients receive the right medications in a controlled and timely manner. They also play a pivotal role in patient education, helping individuals understand the proper use and potential side effects of endocrinology drugs. Moreover, hospital pharmacies collaborate with endocrinologists to ensure tailored treatment plans, often involving complex medication regimens, are effectively implemented. Hence, hospital pharmacies are vital components of the endocrinology drugs market, facilitating optimal patient care and management of endocrine disorders.
Region with largest share:
North America commanded the largest market share during the extrapolated period due to the growing ageing population, which increases the risk of endocrine disorders. Increases in the incidence of a number of endocrine disorders, including diabetes, insulin resistance, and thyroid issues, can be attributed to the rise in obesity cases in the US and Canada. The most prevalent endocrine condition, diabetes, has a high prevalence and contributes significantly to regional market income. Moreover, the American Association of Diabetes Educators and the American Diabetes Association, among other groups, are driving the expansion of the patient education sector in the region.
Region with highest CAGR:
Asia- Pacific region is expected to witness profitable growth over the projection period, owing to a rise in the prevalence of growth hormone deficiency and the expected growth of research and development in the region. The market for endocrinology drugs in the area will benefit from an increase in the incidence of cancers related to the endocrine system and diabetes, including end-stage renal disease. Furthermore, throughout the duration of the estimated time frame, rising public awareness of infrequently occurring endocrine disorders—such as dyspareunia and vulvar and vaginal atrophy caused by menopause—is anticipated to fuel the market's growth. Various research paradigms carried out, such as the introduction of novel drugs and combination pharmaceuticals for the treatment of endocrine disorders, are also expected to boost the region’s growth.
Key players in the market
Some of the key players in the Endocrinology Drugs Market include Abbott Laboratories, Eli Lilly And Company, F. Hoffmann La Roche Ltd., Novartis International AG, Pfizer Inc., Alacer Corporation , Novo Nordisk A/S, Facet Biotech Corporation, Sanofi, Takeda Pharmaceutical Company Limited, Merck KGaA, AstraZeneca Plc, Lee Pharmaceuticals, MannKind, Acerus Pharmaceuticals Corp, Bayer AG, Endo International Plc, Beta Cell NV, Hanmi Pharm Co. Ltd and Ipsen Pharma.
Key Developments:
In March 2023, Eton Pharmaceuticals, a pharmaceutical company focused on developing and commercializing treatments for rare diseases, acquired a rare disease product candidate, ET-600, from Tulex Pharmaceuticals. ET-600 is an innovative product candidate under development for treating an endocrinology condition estimated to impact less than 5,000 pediatric patients in the United States.
In February 2023, Akums Drugs and Pharmaceutical Limited, a contract drug manufacturing company, received approval from the Drug Controller-General of India (DCGI) for their product Lobeglitazone, an anti-diabetic drug. The drug is a new formulation manufactured specifically for type 2 diabetic patients by helping them improve pancreatic beta-cell function.
Therapy Areas Covered:
• Diabetes Drugs
• Growth Hormone Disorders
• Thyroid Hormone Disorder Drugs
• Testosterone Replacement Therapy
• Osteoporosis
• Adrenal insufficiency
• Hypogonadism
• Other Therapy Areas
Distribution Channels Covered:
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Other Distribution Channels
Route of Administrations Covered:
• Oral
• Transdermal
• Injectable
End Users Covered:
• Ambulatory Surgical Centers
• Hospitals
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 End User Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Endocrinology Drugs Market, By Therapy Area
5.1 Introduction
5.2 Diabetes Drugs
5.3 Growth Hormone Disorders
5.4 Thyroid Hormone Disorder Drugs
5.5 Testosterone Replacement Therapy
5.6 Osteoporosis
5.7 Adrenal insufficiency
5.8 Hypogonadism
5.9 Other Therapy Areas
6 Global Endocrinology Drugs Market, By Distribution Channel
6.1 Introduction
6.2 Hospital Pharmacies
6.3 Online Pharmacies
6.4 Retail Pharmacies
6.5 Other Distribution Channels
7 Global Endocrinology Drugs Market, By Route of Administration
7.1 Introduction
7.2 Oral
7.3 Transdermal
7.4 Injectable
8 Global Endocrinology Drugs Market, By End User
8.1 Introduction
8.2 Ambulatory Surgical Centers
8.3 Hospitals
8.4 Other End Users
9 Global Endocrinology Drugs Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Abbott Laboratories,
11.2 Eli Lilly And Company
11.3 F. Hoffmann La Roche Ltd.
11.4 Novartis International AG
11.5 Pfizer Inc.
11.6 Alacer Corporation
11.7 Novo Nordisk A/S
11.8 Facet Biotech Corporation
11.9 Sanofi
11.10 Takeda Pharmaceutical Company Limited
11.11 Merck KGaA
11.12 AstraZeneca Plc
11.13 Lee Pharmaceuticals
11.14 MannKind
11.15 Acerus Pharmaceuticals Corp
11.16 Bayer AG
11.17 Endo International Plc
11.18 Beta Cell NV
11.19 Hanmi Pharm Co. Ltd
11.20 Ipsen Pharma
List of Tables
1 Global Endocrinology Drugs Market Outlook, By Region (2021-2030) ($MN)
2 Global Endocrinology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
3 Global Endocrinology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
4 Global Endocrinology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
5 Global Endocrinology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
6 Global Endocrinology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
7 Global Endocrinology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
8 Global Endocrinology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
9 Global Endocrinology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
10 Global Endocrinology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
11 Global Endocrinology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
12 Global Endocrinology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
13 Global Endocrinology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
14 Global Endocrinology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
15 Global Endocrinology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
16 Global Endocrinology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
17 Global Endocrinology Drugs Market Outlook, By Oral (2021-2030) ($MN)
18 Global Endocrinology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
19 Global Endocrinology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
20 Global Endocrinology Drugs Market Outlook, By End User (2021-2030) ($MN)
21 Global Endocrinology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
22 Global Endocrinology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
23 Global Endocrinology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
24 North America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
25 North America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
26 North America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
27 North America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
28 North America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
29 North America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
30 North America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
31 North America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
32 North America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
33 North America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
34 North America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
35 North America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
36 North America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
37 North America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
38 North America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
39 North America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
40 North America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
41 North America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
42 North America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
43 North America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
44 North America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
45 North America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
46 North America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
47 Europe Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
48 Europe Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
49 Europe Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
50 Europe Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
51 Europe Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
52 Europe Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
53 Europe Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
54 Europe Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
55 Europe Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
56 Europe Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
57 Europe Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
58 Europe Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
59 Europe Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
60 Europe Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
61 Europe Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
62 Europe Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
63 Europe Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
64 Europe Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
65 Europe Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
66 Europe Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
67 Europe Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
68 Europe Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
69 Europe Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
70 Asia Pacific Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
71 Asia Pacific Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
72 Asia Pacific Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
73 Asia Pacific Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
74 Asia Pacific Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
75 Asia Pacific Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
76 Asia Pacific Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
77 Asia Pacific Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
78 Asia Pacific Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
79 Asia Pacific Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
80 Asia Pacific Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
81 Asia Pacific Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
82 Asia Pacific Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
83 Asia Pacific Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
84 Asia Pacific Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
85 Asia Pacific Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
86 Asia Pacific Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
87 Asia Pacific Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
88 Asia Pacific Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
89 Asia Pacific Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
90 Asia Pacific Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
91 Asia Pacific Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
92 Asia Pacific Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
93 South America Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
94 South America Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
95 South America Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
96 South America Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
97 South America Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
98 South America Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
99 South America Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
100 South America Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
101 South America Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
102 South America Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
103 South America Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
104 South America Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
105 South America Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
106 South America Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
107 South America Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
108 South America Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
109 South America Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
110 South America Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
111 South America Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
112 South America Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
113 South America Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
114 South America Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
115 South America Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
116 Middle East & Africa Endocrynology Drugs Market Outlook, By Country (2021-2030) ($MN)
117 Middle East & Africa Endocrynology Drugs Market Outlook, By Therapy Area (2021-2030) ($MN)
118 Middle East & Africa Endocrynology Drugs Market Outlook, By Diabetes Drugs (2021-2030) ($MN)
119 Middle East & Africa Endocrynology Drugs Market Outlook, By Growth Hormone Disorders (2021-2030) ($MN)
120 Middle East & Africa Endocrynology Drugs Market Outlook, By Thyroid Hormone Disorder Drugs (2021-2030) ($MN)
121 Middle East & Africa Endocrynology Drugs Market Outlook, By Testosterone Replacement Therapy (2021-2030) ($MN)
122 Middle East & Africa Endocrynology Drugs Market Outlook, By Osteoporosis (2021-2030) ($MN)
123 Middle East & Africa Endocrynology Drugs Market Outlook, By Adrenal insufficiency (2021-2030) ($MN)
124 Middle East & Africa Endocrynology Drugs Market Outlook, By Hypogonadism (2021-2030) ($MN)
125 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Therapy Areas (2021-2030) ($MN)
126 Middle East & Africa Endocrynology Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
127 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
128 Middle East & Africa Endocrynology Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
129 Middle East & Africa Endocrynology Drugs Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
130 Middle East & Africa Endocrynology Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
131 Middle East & Africa Endocrynology Drugs Market Outlook, By Route of Administration (2021-2030) ($MN)
132 Middle East & Africa Endocrynology Drugs Market Outlook, By Oral (2021-2030) ($MN)
133 Middle East & Africa Endocrynology Drugs Market Outlook, By Transdermal (2021-2030) ($MN)
134 Middle East & Africa Endocrynology Drugs Market Outlook, By Injectable (2021-2030) ($MN)
135 Middle East & Africa Endocrynology Drugs Market Outlook, By End User (2021-2030) ($MN)
136 Middle East & Africa Endocrynology Drugs Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
137 Middle East & Africa Endocrynology Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
138 Middle East & Africa Endocrynology Drugs Market Outlook, By Other End Users (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
